 LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 26, 2021 GLOBE NEWSWIRE -- uniQure N.V. NASDAQ: QURE, a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced today that the U.S. Food and Drug Administration FDA has removed the clinical hold on the Companys hemophilia B gene therapy program after determining the Company satisfactorily addressed all issues identified by the FDA related to a single patient diagnosed with hepatocellular carcinoma HCC in the HOPE-B pivotal trial. 